Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Eli Lilly took a notable step toward closing the obesity treatment access gap in March 2026. The company launched a direct-to-employer platform that lets businesses offer its weight loss drug Zepbound to workers outside the traditional insurance system.
The program is called Employer Connect. It went live on March 5 and connects employers with more than 15 independent program administrators. Together, they help structure obesity benefits in new ways. Through the platform, Zepbound’s multi-dose injectable form is available to network pharmacies at $449 per month. That price applies to all doses and is less than half the drug’s standard list price of over $1,000.
Unlike conventional pharmacy benefit arrangements, this model involves no rebates. Employers see the net cost upfront. Lilly says this makes it easier for companies to plan budgets and decide whether to offer coverage.
Obesity affects more than 100 million American adults. It carries an estimated $1.7 trillion annual economic burden. Despite that scale, roughly half of commercially insured employees currently have no coverage for prescription weight management medications.
Employer Connect targets that gap directly. Rather than routing access through traditional pharmacy benefit managers, companies can connect with a range of third-party administrators. These range from basic benefits coordinators to platforms offering full wraparound care. Partners include Calibrate Health, Teladoc Health, GoodRx, and Cost Plus Drugs. HealthDyne and Humana’s CenterWell pharmacies handle dispensing.
What employees actually pay out of pocket will vary. The cost depends on the arrangement their employer negotiates with the program administrator. In most cases, the final amount will likely fall below the $449 acquisition price.
Zepbound contains tirzepatide. It works by activating two hormone receptors involved in blood sugar regulation and appetite, specifically GLP-1 and GIP. The FDA approved its use as an adjunct to a reduced-calorie diet and increased physical activity. It targets adults with a body mass index of 30 or higher. It also covers those with a BMI of 27 or higher who carry at least one weight-related health condition.
Clinical data back its use. In the 72-week Phase 3 SURMOUNT-1 trial, patients lost an average of 15.0%, 19.5%, or 20.9% of body weight at the 5, 10, and 15 mg doses, respectively. Those results drove strong prescribing growth and increased interest from both employers and federal payers in securing reliable access.
The Employer Connect launch fits into a broader access effort. In November 2025, Lilly reached a federal agreement to cap monthly out-of-pocket costs for Medicare beneficiaries at $50. That program took effect as early as April 1, 2026. States also retain the option to expand access through Medicaid under the same agreement.
On the commercial side, Employer Connect operates separately from LillyDirect. Lilly runs that channel as its direct-to-consumer option for patients managing obesity, diabetes, and migraine.
Lilly’s first quarter 2026 results reflected strong momentum across its GLP-1 portfolio. Mounjaro brought in $8.7 billion, up 125% year over year. Zepbound contributed $4.2 billion, an 80% increase. The quarter also marked the first with Foundayo (orforglipron) on the market, the company’s newly approved oral GLP-1 receptor agonist.
These developments reflect a shift in how Lilly approaches distribution, not just clinical performance. The stated goal is to reach the large share of patients who want treatment but have so far found it financially or logistically out of reach.
